Anticipate generic drug launch
Manage your formulary budget
Find generic entry opportunities
Proactively manage your pharmacy inventory
Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
|Abstract:||A pharmaceutical composition for oral administration in dosage unit form which comprises at least one xanthine derivative selected from the group consisting of (a) (.omega.-1(-hydroxyalkyl-dialkylxanthines wherein the (.omega.-1)-hydroxyalkyl group contains 5 or 6 carbon atoms and is in the 1- or 7-position, the alkyl group in the other of the 1- and 7-position contains from 1 to 12 carbon atoms and the alkyl group in the 3-position contains from 1 to 4 carbon atoms, (b) (.omega.-1)-oxoalkyl-dimethylxanthines wherein the (.omega.-1)-oxoalkyl group contains 5 or 6 carbon atoms and is in the 1- or 7-position, (c) dimethylxanthine derivatives having an additional alkyl group containing from 4 to 12 carbon atoms in the 1- or 7-position, and (d) dimethylxanthine derivatives having an additional benzyl group in the 1- or 7-position and a saliva forming agent, each dosage unit containing at least 300 mg of xanthine derivative, and the weight ratio of xanthine derivative to saliva forming agent being in the range from 1:2 to 10:1 and a method for the preparation of said composition.|
|Inventor(s):||Gleixner; Klaus (Taunusstein-Wehen, DE), Muller; Roland (Wiesbaden, DE), Lehrach; Franz (Wiesbaden, DE)|
|Assignee:||Hoechst Aktiengesellschaft (Frankfurt, DE)|
Patent Claim Types:|
see list of patent claims
|Composition; Dosage form; Process;|
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|Germany||2520978||May 10, 1975|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.